[go: up one dir, main page]

AR065812A1 - Compuesto, composicion farmaceutica y metodos para tratar un trastorno relacionados con pi3k o con mtor, y proceso para sintetizar el compuesto - Google Patents

Compuesto, composicion farmaceutica y metodos para tratar un trastorno relacionados con pi3k o con mtor, y proceso para sintetizar el compuesto

Info

Publication number
AR065812A1
AR065812A1 ARP080101181A ARP080101181A AR065812A1 AR 065812 A1 AR065812 A1 AR 065812A1 AR P080101181 A ARP080101181 A AR P080101181A AR P080101181 A ARP080101181 A AR P080101181A AR 065812 A1 AR065812 A1 AR 065812A1
Authority
AR
Argentina
Prior art keywords
alkyl
amino
nhc
optionally substituted
hydroxyl
Prior art date
Application number
ARP080101181A
Other languages
English (en)
Inventor
J Kaplan
Derek Cecil Cole
Matthew Gregory Bursavich
J Verheijen
D J Richard
M Lefever
Pawel Wojciech Nowak
A Zask
K J Curran
D Malwitz
S Ayral-Kaloustian
K Yu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR065812A1 publication Critical patent/AR065812A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Análogo de pirazolopirimidina utilizables como inhibidores de cinasa mTOR y cinasa PI3, métodos para elaborar los análogos de pirazolopirimidina, composiciones que comprenden un análogo de pirazolopirimidina y métodos para tratar trastornosrelacionados con mTOR que comprende administrar a un sujeto en necesidad de este una cantidad efectiva de un análogo de pirazolopirimidina así como el tratamiento de trastornos relacionados PI3K que comprende administrar una cantidad efectiva de unanálogo de pirazolopirimidina a un sujeto. util para el cáncer, aterosclerosis, artritis, psoriasis, rinon. Reivindicacion 1: Un compuesto de la formula (1) o una sal farmacéuticamente aceptable o tautomero de estos, en donde: R1, es como enformula (2), X5, es -O-, -CH2-O-, o -S(O)n-, y uno cualquiera o más de los átomos de hidrogeno en el anillo de R1 se pueden reemplazar independientemente con alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-3, acilo C1-3, alcoxicarbonilo C1-3, amino(alquilo C1-6), hidroxilo, fluor, o -CN, en donde cualquiera de los dos átomos de hidrogeno adherido al mismo átomo de carbono de R1 se pueden reemplazar por un átomo de oxígeno, formando un carbonilo (C=O); n es un entero de 0 a 2; R2 es a)arilo C6-14 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de: b) (i) halogeno, (ii) alquilo C1-6 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de halogeno, heterociclo, -NH2, -NH(alquilo C1-6), -N(alquilo C1-6)(alquilo C1-6), -N(alquilo C1-3)C(O)(alquilo C1-6), -NHC(O)(alquilo C1-6), -NHC(O)H, -C(O)NH2, -C(O)NH(alquilo C1-6), -C(O)N(alquilo C1-6)(alquilo C1-6), -CN, hidroxilo, alcoxi C1-6, alquilo C1-6, -C(O)OH, -C(O)O(alquilo C1-6), -C(O)(alquilo C1-6), arilo C6-14, heteroarilo C1-9, y cicloalquilo C3-8, (iii) alcoxi C1-6 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de halogeno, -NH2, -NH(alquilo C1-6), -N(alquilo C1-6)(alquilo C1-6), -N(alquilo C1-3)C(O)(alquilo C1-6), -NHC(O)(alquilo C1-6), -NHC(O)H, -C(O)NH2, -C(O)NH(alquilo C1-6), -C(O)N(alquilo C1-6)(alquilo C1-6), -CN, hidroxilo, alcoxi C1-6, alquilo C1-6, -C(O)OH, -C(O)O(alquilo C1-6), -C(O)(alquilo C1-6), arilo C6-14, heteroarilo C1-9, y cicloalquilo C3-8, (iv) alcoxicarbonilo C1-6, (v) alquenilo C2-6 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de halogeno, -NH2, -NH(alquilo C1-6), -N(alquilo C1-6)(alquiloC1-6), -N(alquilo C1-3)C(O)(alquilo C1-6), -NHC(O)(alquilo C1-6), -NHC(O)H, -C(O)NH2, -C(O)NH(alquilo C1-6), -C(O)N(alquilo C1-6)(alquilo C1-6), -CN, hidroxilo, alcoxi C1-6, alquilo C1-6, -C(O)OH, -C(O)O(alquilo C1-6), -C(O)(alquilo C1-6), arilo C6-14, heteroarilo C1-9, y cicloalquilo C3-8, (vi) alquinilo C2-6 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de halogeno, -NH2, - NH(alquilo C1-6), -N(alquilo C1-6)(alquilo C1-6), -N(alquilo C1-3)C(O)(alquiloC1-6), -NHC(O)(alquilo C1-6), -NHC(O)H, -C(O)NH2, -C(O)NH(alquilo C1-6), -C(O)N(alquilo C1-6)(alquilo C1-6), -CN, hidroxilo, alcoxi C1-6, alquilo C1-6, -C(O)OH, -C(O)O(alquilo C1-6), -C(O)(alquilo C1-6), arilo C6-14, heteroarilo C1-9, y cicloalquiloC3-8, (vii) cicloalquilo C3-8 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de alquilo C1-6, halo, halo(alquilo C1-6)-, hidroxilo, -O-alquilo C1-6, -NH2, amino(alquilo C1-6)-, (alquilo C1-6)amino-, di(alquiloC1-6)amino-, -COOH, -C(O)O-(alquilo C1-6), -OC(O)-(alquilo C1-6), (alquilo C1-6)carboxiamido-, -C(O)NH2, carboxiamidoalquil- y -NO2, (viii) arilo C6-14 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de alquiloC1-6, halo, halo(alquilo C1-6)-, hidroxilo, hidroxialquilo C1-6, -NH2, amino(alquilo C1-6)-, (alquilo C1-6)amino-, di(alquilo C1-6)amino-, -COOH, -C(O)O-(alquilo C1-6), -OC(O)-(alquilo C1-6), (alquilo C1-6)carboxiamido-, -C(O)NH2, (alquilo C1-6)N-alquilamido-, y -NO2, (ix) heteroarilo C1-9 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de alquilo C1-6, halo, halo(alquilo C1-6)-, hidroxilo, hidroxialquilo C1-6, -NH2, amino(alquilo C1-6)-, (alquilo C1-6)amino-, di(alquilo C1-6)amino-, -COOH, -C(O)O-(alquilo C1-6), -OC(O)-(alquilo C1-6), (alquilo C1-6)carboxiamido-, -C(O)NH2, (alquilo C1-6)N-alquilamido-, y -NO2, (x) perfluoroalquilo C1-6-, (xi) hidroxilo, (xii) NR16R17, (xiii) NO2, (xiv) CN, (xv)CO2H, (xvi) CF3, (xvii) CF3O, (xviii) alquiltio C1-6, (xix) -SO2NR16R17, (xx) -O-C(O)NR16R17, (xxi) -C(O)NR16R17, (xxii) NR17C(O)R16, (xxiii) N(alquilo C1-6)C(O)R16, (xxiv) -NHC(O)NR16R17, (xxv) -NHC(O)NHNR16R17, (xxvi) -NHC(O)OR18, (xxvii) -NHC(O)NHOR16, (xxviii) -NH(SO2)NH-(alquilo C1-6), (xxix) -NH(SO2)-(alquilo C1-6), (xxx) -NH(SO2)NH-arilo C6-14, (xxxi) -NHC(S)-NH-alquilo C1-6, (xxxii) -N=C(S-alquilo C1-6)(NH-alquilo C1-6), (xxxiii) -S(O)p-arilo C6-14, (xxxiv) -S(O)p-heteroarilo C1-9, (xxxv) -N(H)-C(=N-(CN))-(NR16R17), y (xxxvi) -N(H)-C(=N-(CN))(O-R16), c) heteroarilo C1-9 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de: (i) halogeno, (ii) alquilo C1-6 opcionalmente sustituido con de 1a 3 sustituyentes independientemente seleccionados de halogeno. -NH2, -NH(alquilo C1-6), -N(alquilo C1-6)(alquilo C1-6), -N(alquilo C1-3)C(O)(alquilo C1-6), -NHC(O)(alquilo C1-6), -NHC(O)H, -C(O)NH2, -C(O)NH(alquilo C1-6), -C(O)N(alquilo C1-6)(alquilo C1-6), -CN, hidroxilo, alcoxi C1-6, alquilo C1-5, -C(O)OH, -C(O)O(alquilo C1-6), -C(O)(alquilo C1-6), arilo C6-14, heteroarilo C1-9, y cicloalquilo C3-8, (iii) alcoxi C1-6 opcionalmente sustituido con de 1 a 3 sustituyentesindependientemente seleccionados de halogeno, -NH2, -NH(alquilo C1-6), -N(alquilo C1-6)(alquilo C1-6), -N(alquilo C1-3)C(O)(alquilo C1-6), -NHC(O)(alquilo C1-6), -NHC(O)H, -C(O)NH2, -C(O)NH(alquilo C1-6), -C(O)N(alquilo C1-6)(alquilo C1-6), -CN,hidroxilo, alcoxi C1-6, alquilo C1-6, -C(O)OH, -C(O)O(alquilo C1-6), -C(O)(alquilo C1-6), arilo C6-14, heteroarilo C1-9, y cicloalquilo C3-8, (iv) alcoxicarbonilo C1-6, (v) alquenilo C2-6 opcionalmente sustituido con de 1 a 3 sustituyentesindependientemente seleccionados de halogeno, -NH2, -NH(alquilo C1-6), -N(alquilo C1-6)(alquilo C1-6), -N(alquilo C1-3)C(O)(alquilo C1-6), -NHC(O)(alquilo C1-6), -NHC(O)H, -C(O)NH2, -C(O)NH(alquilo C1-6), -C(O)N(alquilo C1-6)(alquilo C1-6), -CN,hidroxilo, alcoxi C1-6, alquilo C1-6, -C(O)OH, -C(O)O(alquilo C1-6), -C(O)(alquilo C1-6), arilo C6-14, heteroarilo C1-9, y cicloalquilo C3-8, (vi) alquinilo C2-6 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados dehalogeno, -NH2, - NH(alquilo C1-6), -N(alquilo C1-6)(alquilo C1-6), -N(alquilo C1-3)C(O)(alquilo C1-6), -NHC(O)(alquilo C1-6), -NHC(O)H, -C(O)NH2, -C(O)NH(alquilo C1-6), -C(O)N(alquilo C1-6)(alquilo C1-6), -CN, hidroxilo, alcoxi C1-6, alquilo C1-6, -C(O)OH, -C(O)O(alquilo C1-6), -C(O)(alquilo C1-6), arilo C6-14, heteroarilo C1-9, y cicloalquilo C3-8, (vii) cicloalquilo C3-8 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de alquilo C1-6, halo, halo(alquiloC1-6)-, hidroxilo, -O-alquilo C1-6, -NH2, amino(alquilo C1-6)-, (alquilo C1-6)amino-, di(alquilo C1-6)amino-, -COOH, -C(O)O-(alquilo C1-6), -OC(O)-(alquilo C1-6), (alquilo C1-6)carboxiamido-, -C(O)NH2, carboxiamidoalquil- y -NO2, (viii) arilo C6-14opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de alquilo C1-6, halo, halo(alquilo C1-6)-, hidroxilo, hidroxialquilo C1-6, -NH2, amino(alquilo C1-6)-, (alquilo C1-6)amino-, di(alquilo C1-6)amino-, -COOH, -C(O)O-(alquilo C1-6), -OC(O)-(alquilo C1-6), (alquilo C1-6)carboxiamido-, -C(O)NH2, (alquilo C1-6)N-alquilamido-, y -NO2, (ix) heteroarilo C1-9 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de alquilo C1-6, halo,halo(alquilo C1-6)-, hidroxilo, hidroxialquilo C1-6, -NH2, amino(alquilo C1-6)-, (alquilo C1-6)amino-, di(alquilo C1-6)amino-, -COOH, -C(O)O-(alquilo C1-6), -OC(O)-(alquilo C1-6), (alquilo C1-6)carboxiamido-, -C(O)NH2, (alquilo C1-6)N-alquilamido-,y -NO2, (x) perfluoroalquilo C1-6-, (xi) hidroxilo, (xii) NR16R17, (xiii) NO2, (xiv) CN, (xv) CO2H, (xvi) CF3, (xvii) CF3O, (xviii) alquiltio C1-6, (xix) -SO2NR16R17,(xx) -C(O)NR16R17, (xxi) NR17C(O)R16, (xxii) -NHC(O)NR16R17, (xxiii) -NHC(O)NHNR16R17, (xxiv) -NHC(O)OR18, (xxv) -NHC(O)NHOR16, (xxvi) -NH(SO2)NH-alquilo C1-6, (xxvii) -NH(SO2)NH-arilo C6-14, (xxviii) -NHC(S)-NH-alquilo C1-6, (xxix) -N=C(S-alquilo C1-6)(NH-alquilo C1-6), (xxx) -S(O)p-arilo C6-14, (xxxi) -S(O)p-heteroarilo C1-9, (xxxii) -N(H)-C(N-(CN))-(NR16R17), (xxxiii) -N(H)-C(N-(CN))-(O-R16), y (xxxiv) -N(H)-C(=N-(CN))-(O-arilo C6-14); d) -HC=CH-arilo C6-14; e) heterociclo adherido al átomo de carbono en el anillo del heterociclo; f) o -HC=CH-heteroarilo C1-9; R16 y R17 son cada uno independientemente a) H; b) alcoxi C1-6 c) perfluoroalquilo C1-6, d) arilo C6-14 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de: (i) alquilo C1-6 en donde el alquiloC1-6 se sustituye opcionalmente con uno o más sustituyentes independientemente seleccionados de: A) heterociclo opcionalmente sustituido con alquilo C1-6, B) NH2-, C) (alquilo C1-6)amino-, y D) di(alquilo C1-6)amino-, (ii) alcoxi C1-6, (iii) halo,(iv) halo(alquilo C1-6)-, (v) hidroxilo, (vi) hidroxialquilo C1-6, (vii) heterociclo opcionalmente sustituido con alquilo C1-6, (viii) NH2, (ix) amino(alquilo C1-6)-, (x) (alquilo C1-6)amino-, (xi) di(alquilo C1-6)amino-, (xii) alcoxi C1-6-alquilenoC1-6-NH-alquileno C1-6-, (xiii) hidroxialquilo C1-6-NH-alquileno C1-6-, (xiv) amino(alquilo C1-6)-NH-alquileno C1-6-, (xv) di(alquilo C1-6)amino-alquileno C1-6-NH-alquiIeno C1-6-, (xvi) hidroxialquilo C1-6-NH-, (xvii) amino(alquilo C1-6)-NH-,(xviii) -COOH, (xix) -C(O)O-(alquilo C1-6), (xx) -OC(O)-(alquilo C1-4), (xxi) (alquilo C1-6)carboxiamido-, (xxii) -C(O)NH2, (xxiii) (alquilo C1-6)N-alquilamido-, (xxiv) alc
ARP080101181A 2007-03-21 2008-03-19 Compuesto, composicion farmaceutica y metodos para tratar un trastorno relacionados con pi3k o con mtor, y proceso para sintetizar el compuesto AR065812A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91930107P 2007-03-21 2007-03-21

Publications (1)

Publication Number Publication Date
AR065812A1 true AR065812A1 (es) 2009-07-01

Family

ID=39766744

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101181A AR065812A1 (es) 2007-03-21 2008-03-19 Compuesto, composicion farmaceutica y metodos para tratar un trastorno relacionados con pi3k o con mtor, y proceso para sintetizar el compuesto

Country Status (13)

Country Link
US (1) US20080234262A1 (es)
EP (1) EP2078021A2 (es)
JP (1) JP2010522195A (es)
CN (1) CN101675051A (es)
AR (1) AR065812A1 (es)
AU (1) AU2008228964A1 (es)
BR (1) BRPI0809239A2 (es)
CA (1) CA2681501A1 (es)
CL (1) CL2008000815A1 (es)
MX (1) MX2009010132A (es)
PE (1) PE20081888A1 (es)
TW (1) TW200900404A (es)
WO (1) WO2008115974A2 (es)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2264819C (en) * 1996-09-04 2010-03-23 Intertrust Technologies Corp. Trusted infrastructure support systems, methods and techniques for secure electronic commerce, electronic transactions, commerce process control and automation, distributed computing, and rights management
CA2692720A1 (en) * 2007-07-09 2009-01-15 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
CA2710194C (en) 2007-12-19 2014-04-22 Amgen Inc. Inhibitors of p13 kinase
US8841312B2 (en) 2007-12-19 2014-09-23 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
JP5608099B2 (ja) * 2008-01-30 2014-10-15 ジェネンテック， インコーポレイテッド ピラゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法
JP5530422B2 (ja) 2008-04-07 2014-06-25 アムジエン・インコーポレーテツド 細胞周期阻害薬としてのｇｅｍ−二置換およびスピロ環式アミノピリジン／ピリミジン
KR20110046514A (ko) * 2008-07-31 2011-05-04 제넨테크, 인크. 피리미딘 화합물, 조성물 및 사용 방법
SI2350075T1 (sl) 2008-09-22 2014-06-30 Array Biopharma, Inc. Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
SG10201914059WA (en) 2008-10-22 2020-03-30 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
JP5877064B2 (ja) * 2008-11-11 2016-03-02 エックスカバリー ホールディング カンパニー エルエルシー ＰＩ３Ｋ／ｍＴＯＲキナーゼ阻害剤
US8785457B2 (en) 2009-03-13 2014-07-22 Cellzome Limited Pyrimidine derivatives as mTOR inhibitors
JP5766177B2 (ja) * 2009-03-27 2015-08-19 ベトディーシー，インコーポレイテッド ピリミジニル及び１，３，５−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用
EP2414361A1 (en) 2009-03-31 2012-02-08 ArQule, Inc. Substituted heterocyclic compounds
US20120114637A1 (en) * 2009-05-04 2012-05-10 Santen Pharmaceutical Co., Ltd. Mtor pathway inhibitors for treating ocular disorders
CN102480961A (zh) * 2009-06-24 2012-05-30 健泰科生物技术公司 与含氧杂环稠合的嘧啶化合物、组合物和使用方法
WO2011002887A1 (en) * 2009-07-02 2011-01-06 Schering Corporation FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS
EP2532659A1 (en) 2009-07-07 2012-12-12 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
HRP20190016T1 (hr) 2009-08-17 2019-03-08 Intellikine, Llc Heterociklički spojevi i njihova upotreba
WO2011031896A2 (en) * 2009-09-09 2011-03-17 Avila Therapeutics, Inc. Pi3 kinase inhibitors and uses thereof
DE102009049679A1 (de) * 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
BR112012011147A2 (pt) * 2009-11-12 2021-09-08 F.Hoffmann-La Roche Ag Composto, composição farmacêutica e uso de um composto.
MX2012005463A (es) * 2009-11-12 2012-09-12 Hoffmann La Roche Compuestos de purina n/9 sustituida, composiciones y metodos de uso.
UA110697C2 (uk) 2010-02-03 2016-02-10 Сігнал Фармасьютікалз, Елелсі ЗАСТОСУВАННЯ ІНГІБІТОРІВ TOR-КІНАЗИ ДЛЯ ЛІКУВАННЯ ПУХЛИННИХ ЗАХВОРЮВАНЬ У ПАЦІЄНТА ЗІ ЗНИЖЕНИМ РІВНЕМ БІЛКА pAMPK ТА/АБО АКТИВНОСТІ AMPK
US9249129B2 (en) 2010-03-04 2016-02-02 Cellzome Limited Morpholino substituted urea derivatives as mTOR inhibitors
KR20130113950A (ko) * 2010-05-19 2013-10-16 엑스커버리 홀딩 컴퍼니 엘엘씨 Ｍｔｏｒ 선택적 키나아제 억제제
EP2918588B1 (en) 2010-05-20 2017-05-03 Array Biopharma, Inc. Macrocyclic compounds as TRK kinase inhibitors
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
WO2012099581A1 (en) 2011-01-19 2012-07-26 Takeda Pharmaceutical Company Limited Dihydrofuropyrimidine compounds
EP2678018A4 (en) 2011-02-23 2015-09-30 Intellikine Llc COMBINATION OF CHINESE HEMMER AND USES THEREOF
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
MY161199A (en) 2011-03-23 2017-04-14 Amgen Inc Fused tricyclic dual inhibitors of cdk 4/6 and flt3
JP6042406B2 (ja) 2011-03-28 2016-12-14 メイ プハルマ，インコーポレーテッド （α−置換アラルキルアミノ及びヘテロアリールアルキルアミノ）ピリミジニル及び１，３，５−トリアジニルベンズイミダゾール、それらを含む医薬組成物、並びに増殖性疾患の治療で使用するためのこれらの化合物
US20140163023A1 (en) 2011-04-04 2014-06-12 Cellzome Limited Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
EP2739751A1 (en) 2011-08-03 2014-06-11 Signal Pharmaceuticals, LLC Identification of gene expression profile as a predictive biomarker for lkb1 status
US9175011B2 (en) 2011-09-21 2015-11-03 Cellzone Limited Morpholino substituted urea or carbamate derivatives as MTOR inhibitors
CN103946222B (zh) 2011-10-07 2016-12-28 塞尔佐姆有限公司 作为mtor抑制剂的吗啉代取代的双环嘧啶脲或氨基甲酸衍生物
CN103130793B (zh) * 2011-11-30 2016-09-21 中国人民解放军军事医学科学院毒物药物研究所 3-(1-芳基哌啶-4-基)-2-芳基噻唑啉-4-酮类化合物、其制备方法及用途
KR20160027218A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
KR20150016406A (ko) * 2012-06-07 2015-02-11 에프. 호프만-라 로슈 아게 탄키라제의 피라졸로피리미돈 및 피라졸로피리돈 억제제
PE20190736A1 (es) 2012-06-13 2019-05-23 Incyte Holdings Corp Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr)
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TWI629275B (zh) * 2013-03-13 2018-07-11 賽諾菲公司 Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途
US9637505B2 (en) 2013-03-15 2017-05-02 Dow Agrosciences Llc 4-amino-6-(heterocyclic)picolinates and 6-amino-2-(heterocyclic)pyrimidine-4-carboxylates and their use as herbicides
CN109134440A (zh) 2013-03-15 2019-01-04 美国陶氏益农公司 除草化合物及其作为除草剂的用途
EP2970186B1 (en) * 2013-03-15 2020-06-10 Dow AgroSciences LLC 4-amino-6-(heterocyclic)picolinates and 6-amino-2-(heterocyclic) pyrimidine-4-carboxylates and their use as herbicides
ES2944478T3 (es) 2013-04-17 2023-06-21 Signal Pharm Llc 1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino[2,3-b]pirazin-2(1H)-ona para tratar el glioblastoma multiforme
MX368286B (es) 2013-04-17 2019-09-27 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
KR102242505B1 (ko) 2013-04-17 2021-04-20 시그날 파마소티칼 엘엘씨 암 치료용 tor 키나제 억제제 및 시티딘 유사체를 포함하는 병용 요법
NZ629411A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
BR112015026257B1 (pt) 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
SG11201508527VA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
AU2014254057A1 (en) 2013-04-17 2015-11-05 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
KR102269032B1 (ko) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
JP6401250B2 (ja) 2013-05-29 2018-10-10 シグナル ファーマシューティカルズ，エルエルシー ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（ｔｒａｎｓ）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン、その固体形態の医薬組成物、及びその使用方法
JP2017510628A (ja) 2014-03-13 2017-04-13 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 縮合ピリミジン系ヒドロキサメート誘導体
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
CA2948587C (en) * 2014-05-14 2018-07-17 Pfizer Inc. Pyrazolopyridines and pyrazolopyrimidines
TWI689252B (zh) 2014-09-15 2020-04-01 美商陶氏農業科學公司 源自於施用吡啶羧酸除草劑與乙醯乳酸合成酶（ａｌｓ）抑制劑的協同性雜草控制
WO2016044276A1 (en) 2014-09-15 2016-03-24 Dow Agrosciences Llc Synergistic weed control from applications of pyridine carboxylic acid herbicides and photosystem ii inhibitors
AR101858A1 (es) 2014-09-15 2017-01-18 Dow Agrosciences Llc Composiciones herbicidas protegidas que comprenden un herbicida de ácido piridincarboxílico
TWI685302B (zh) 2014-09-15 2020-02-21 美商陶氏農業科學公司 包含吡啶羧酸除草劑之安全的除草組成物
TWI689251B (zh) 2014-09-15 2020-04-01 美商陶氏農業科學公司 源自於施用吡啶羧酸除草劑與合成生長素除草劑及/或生長素轉運抑制劑的協同性雜草控制
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10799505B2 (en) 2014-11-16 2020-10-13 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US10172942B2 (en) * 2014-12-17 2019-01-08 Pfizer Inc. Formulations of a PI3K/mTor-inhibitor for intravenous administration
ES2895769T3 (es) 2015-02-20 2022-02-22 Incyte Corp Heterociclos bicíclicos como inhibidores de FGFR
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
JP2018534296A (ja) 2015-10-26 2018-11-22 ロクソ オンコロジー， インコーポレイテッドＬｏｘｏ Ｏｎｃｏｌｏｇｙ， Ｉｎｃ． Ｔｒｋ阻害薬耐性がんにおける点変異およびそれに関連する方法
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
MX386416B (es) 2016-04-04 2025-03-18 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida.
HUE063877T2 (hu) 2016-05-18 2024-02-28 Loxo Oncology Inc (S)-N-(5-((R)-2-(2,5-dlfluorofenil)pirolidin-1-il)plrazolo[1,5-A]pirimidin-3-il) -3-hidroxipirolidin-1-karboxamid elõállítása
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
IL303660A (en) 2017-05-02 2023-08-01 Revolution Medicines Inc Rapamycin analogs as mtor inhibitors
AU2018271862B2 (en) 2017-05-23 2022-12-15 Mei Pharma, Inc. Combination therapy
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
US12291533B2 (en) 2017-08-02 2025-05-06 Northwestern University Substituted fused pyrimidine compounds and uses thereof
JP2020531414A (ja) 2017-08-14 2020-11-05 エムイーアイ ファーマ，インク． 併用療法
CA3098692A1 (en) 2018-05-01 2019-11-07 Revolution Medicines, Inc. C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
WO2019212991A1 (en) 2018-05-01 2019-11-07 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
SI3788047T1 (sl) 2018-05-04 2024-11-29 Incyte Corporation Trdne oblike inhibitorja fgfr in postopki priprave le-teh
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
CN110833551B (zh) * 2018-08-15 2023-03-24 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物在治疗急性胰腺炎的用途
US12054488B2 (en) * 2018-09-27 2024-08-06 Suzhou Raymon Pharmaceuticals Company, Ltd. Pyrazolopyrimidine compound and preparation method therefor and use thereof in preparation of anti-cancer drug
CN111646995B (zh) * 2019-03-04 2023-03-21 四川大学 4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
EP3980010A4 (en) 2019-06-04 2023-06-07 Arcus Biosciences, Inc. 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP3800188A1 (en) * 2019-10-02 2021-04-07 Bayer AG Substituted pyrazolopyrimidines as irak4 inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2022106579A1 (en) * 2020-11-20 2022-05-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compounds for treating a disease associated with macrophage senescence
CN112552312B (zh) * 2020-12-07 2022-08-05 杭州科巢生物科技有限公司 一种瑞卢戈利或其盐的合成方法
MX2023009417A (es) 2021-02-16 2023-12-01 Vaccitech North America Inc Nanopartículas de autoensamblaje basadas en péptidos anfifílicos.
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022268025A1 (zh) * 2021-06-22 2022-12-29 成都苑东生物制药股份有限公司 Atr抑制剂及其用途
AU2023275778A1 (en) 2022-05-25 2024-12-12 Revolution Medicines, Inc. Methods of treating cancer with an mtor inhibitor
CN115304600B (zh) * 2022-09-29 2023-01-13 北京鑫开元医药科技有限公司 mTOR抑制剂、制备方法及用途
IL320235A (en) 2022-10-25 2025-06-01 Barinthus Biotherapeutics North America Inc Self-assembled nanoparticles
CN119841829A (zh) * 2023-10-18 2025-04-18 中国科学院合肥物质科学研究院 用于治疗PI3Kγ介导的疾病的化合物及其用途
CN117586267A (zh) * 2023-11-23 2024-02-23 山东百启生物医药有限公司 一种4-溴吡唑[3,4-d]-嘧啶的制备方法
CN118791413B (zh) * 2024-06-18 2025-04-18 青岛润农化工有限公司 一种丁醚脲的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847908A (en) * 1973-03-05 1974-11-12 Squibb & Sons Inc 6-styrylpyrazolo(3,4-d)pyrimidinones and pyrimidines
MX2007010404A (es) * 2005-02-25 2008-01-11 Kudos Pharm Ltd Hidrazinometilo, hidrazonometilo y compuestos heterociclicos de 5 miembros que actuan como inhibidores de mtor y su uso como agentes anti-cancer.
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
KR20130087054A (ko) * 2006-04-04 2013-08-05 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질

Also Published As

Publication number Publication date
JP2010522195A (ja) 2010-07-01
EP2078021A2 (en) 2009-07-15
CN101675051A (zh) 2010-03-17
AU2008228964A1 (en) 2008-09-25
CA2681501A1 (en) 2008-09-25
MX2009010132A (es) 2009-10-12
AU2008228964A8 (en) 2009-11-19
WO2008115974A2 (en) 2008-09-25
PE20081888A1 (es) 2008-12-20
WO2008115974A3 (en) 2008-12-18
CL2008000815A1 (es) 2008-05-30
BRPI0809239A2 (pt) 2014-11-25
TW200900404A (en) 2009-01-01
US20080234262A1 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
AR065812A1 (es) Compuesto, composicion farmaceutica y metodos para tratar un trastorno relacionados con pi3k o con mtor, y proceso para sintetizar el compuesto
NZ719592A (en) Pyrrolo[2,1-f][1,2,4]triazines useful for treating respiratory syncitial virus infections
MX381326B (es) Derivados de 7h-imidazo[1-5-a]pirazin-8-ona como inhibidores de la fosfodiesterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos
AR077151A1 (es) Compuestos de triazol que portan un sustituyente de azufre x, composiciones farmaceuticas, agricolas y su uso en el tratamiento de cancer o infecciones virales
PE20070335A1 (es) Benzimidazoles sustituidos y metodos para su preparacion
TW200614992A (en) Combinations for the treatment of diseases involving cell proliferation
TW200806299A (en) Treatment of pain
RU2010144637A (ru) Замещенные гамма-лактамы в качестве терапевтических агентов
TR201906123T4 (tr) P13 kinazı ve mtor inhibitörleri olarak triazin bileşikleri.
TNSN08070A1 (en) Benzoquinazoline derivatives and their use in treating bone disorders
AR070540A1 (es) Derivados de 6-oxo-5, 6-dihidro-benzo[c][1, 8]naftiridina, un proceso para su preparacion, un kit que los incluye y su uso en la fabricacion de medicamentos para el tratamiento del cancer.
EA201001017A1 (ru) 3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы
RU2013146659A (ru) Способы лечения рака
MX2007005679A (es) Metodo para tratamiento de desordenes de movimiento.
BR112014015482A8 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
AR063869A1 (es) Metodo de radiosensibilizacion de tumores usando un agente radiosensibilizante
JP2015514063A5 (es)
JP2007500707A5 (es)
PE20061067A1 (es) Derivados de pirimidina
RU2014133744A (ru) Соединения и способы лечения кандидоза и инфекций aspergillus
TW200639159A (en) Treatment of pain
EA200500521A1 (ru) 3-фенилзамещенный пиридоиндолон, его получение и терапевтическое применение
AR055271A1 (es) Compuesto del acido bifenil carboxilico, composicion farmaceutica que lo comprende, su uso para preparar esta ultima y proceso para prepararlo
AR074989A1 (es) Derivados de benzotiazolonas, medicamentos que los contienen ,proceso para prepararlos y uso de los mismos en el tratamiento de tumores.
PL2301908T3 (pl) (-)-stereoizomer 2,6-di-sec-butylofenolu i jego analogi do propagowania działania przeciwwymiotnego, leczenia nudności i wymiotów oraz do leczenia migreny

Legal Events

Date Code Title Description
FB Suspension of granting procedure